CAS 5988-19-2|L-Dihydroorotic acid
| Common Name | L-Dihydroorotic acid | ||
|---|---|---|---|
| CAS Number | 5988-19-2 | Molecular Weight | 158.112 |
| Density | 1.9±0.1 g/cm3 | Boiling Point | 524.0±60.0 °C at 760 mmHg |
| Molecular Formula | C5H6N2O4 | Melting Point | 254-255 °C (dec.)(lit.) |
| MSDS | ChineseUSA | Flash Point | 270.7±32.9 °C |
| Symbol | GHS07 | Signal Word | Warning |
Names
| Name | (S)-dihydroorotic acid |
|---|---|
| Synonym | More Synonyms |
L-Dihydroorotic acid BiologicalActivity
| Description | L-Dihydroorotic acid can reversibly hydrolyze to yield the acyclic L-ureidosuccinic acid by dihydrowhey enzyme[1]. |
|---|---|
| Related Catalog | Research Areas >>Others |
| Target | Human Endogenous Metabolite |
| References | [1]. St. Louis, Missouri,et al. ENZYMATIC SYNTHESIS AND BREAKDOWN OF A PYRIMIDINE, OROTIC ACID.October 28, 1953. |
Chemical & Physical Properties
| Density | 1.9±0.1 g/cm3 |
|---|---|
| Boiling Point | 524.0±60.0 °C at 760 mmHg |
| Melting Point | 254-255 °C (dec.)(lit.) |
| Molecular Formula | C5H6N2O4 |
| Molecular Weight | 158.112 |
| Flash Point | 270.7±32.9 °C |
| Exact Mass | 158.032761 |
| PSA | 95.50000 |
| LogP | -2.29 |
| Vapour Pressure | 0.0±3.1 mmHg at 25°C |
| Index of Refraction | 1.714 |
| InChIKey | UFIVEPVSAGBUSI-REOHCLBHSA-N |
| SMILES | O=C1CC(C(=O)O)NC(=O)N1 |
| Storage condition | Store at 0-5°C |
Safety Information
| Symbol | GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H315-H319-H335 |
| Precautionary Statements | P261-P305 + P351 + P338 |
| Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves |
| Hazard Codes | Xi:Irritant |
| Risk Phrases | R36/37/38 |
| Safety Phrases | S26-S36 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | 3 |
| HS Code | 2934999001 |
Customs
| HS Code | 2934999001 |
|---|
Articles26
More Articles| SEC-TID: A Label-Free Method for Small-Molecule Target Identification. J. Biomol. Screen. 19(6) , 917-927, (2014) Bioactive small molecules are an invaluable source of therapeutics and chemical probes for exploring biological pathways. Yet, significant hurdles in drug discovery often come from lacking a comprehen... | |
| The structures of human dihydroorotate dehydrogenase with and without inhibitor reveal conformational flexibility in the inhibitor and substrate binding sites. Biochemistry 47(34) , 8929-36, (2008) Inhibitors of dihydroorotate dehydrogenase (DHODH) have been suggested for the treatment of rheumatoid arthritis, psoriasis, autoimmune diseases, Plasmodium, and bacterial and fungal infections. Here ... | |
| Miller (Genee-Wiedemann) syndrome represents a clinically and biochemically distinct subgroup of postaxial acrofacial dysostosis associated with partial deficiency of DHODH. Hum. Mol. Genet. 21(18) , 3969-83, (2012) Biallelic mutations in the gene encoding DHOdehase [dihydroorotate dehydrogenase (DHODH)], an enzyme required for de novo pyrimidine biosynthesis, have been identified as the cause of Miller (Genée-We... |
Synonyms
| (S)-dihydroorotic acid |
| dihydroorotate |
| MFCD00085339 |
| (S)-2,6-Dioxohexahydro-4-pyrimidinecarboxylic acid |
| (S)-2,6-dioxo-hexahydro-pyrimidine-4-carboxylic acid |
| 4-Pyrimidinecarboxylic acid, 4,5-dihydro-2,6-dihydroxy-, (4S)- |
| (4S)-2,6-Dioxohexahydropyrimidine-4-carboxylic acid |
| (4S)-2,6-Dihydroxy-4,5-dihydro-4-pyrimidinecarboxylic acid |
| L-Dihydroorotic Acid |
| (4S)-2,6-Dioxohexahydro-4-pyrimidinecarboxylic acid |
| EINECS 204-352-8 |
| 4-Pyrimidinecarboxylic acid, hexahydro-2,6-dioxo-, (4S)- |
